1. Sulodexide, or one of its components, or a mixture thereof, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate thereof, for use in the treatment of a pathology in which matrix metalloproteinases (MMPs) are involved. 2. Sulodexide according to claim 1, wherein said component is dermatan sulfate. Sulodexide according to claim 1, where the specified component is a low molecular weight heparin. Sulodexide according to claim 1, where MMP is MMP-9.5. Sulodexide according to claim 1, wherein said pathology is an infection or a neoplastic disease. Sulodexide according to any one of claims 1 to 4, wherein said pathology is selected from the group consisting of vascular disease, gastrointestinal ulcers, cardiovascular disease caused by diabetes, pathogenesis of inflammation, relaxation of veins, enlargement and development of the tumor, growth of the primary tumor, angiogenesis, extravasation and intravation of neoplastic cells and their combination. 7. Sulodexide according to claim 6, wherein said vascular disease is selected from the group consisting of chronic venous insufficiency (CVI), varicose veins, cardiac rupture after myocardial infarction, abdominal aortic aneurysm. Sulodexide according to claim 1 for use in inhibiting or reducing the level of MMP by more than 20%. Sulodexide of claim 8 for use in inhibiting or decreasing the level of MMP-9 by more than 20% .10. Dermatan sulfate and low molecular weight heparin obtained with sulodexide. 11. The method of producing dermatan sulfate according to claim 10, comprising the following stages: a) preparing an affinity chromatographic column with ATIII in a concentration of 5 to 10 mg / ml gel； b) loading sulodexide into the specified column from stage a) into a concentrate1. Сулодексид, или один из его компонентов, или их смесь, или их фармацевтически приемлемая соль, сольват, гидрат, клатрат, для применения в лечении патологии, в которую вовлечены матриксные металлопротеиназы (ММР).2. Сулодексид по п.1,
